Alfica Sehgal
Chief Scientific Officer Judo Biosciences
Alfica Sehgal, PhD, is the Chief Scientific Officer at Judo Bio and an Entrepreneur-in-Residence at Atlas Venture. A seasoned leader in RNA therapeutics and translational science, she brings over 15 years of experience from prominent roles at Alnylam Pharmaceuticals and CAMP4 Therapeutics, where she served as Head of Discovery and Translation. Dr. Sehgal has a proven track record of advancing novel therapeutic programs from discovery toward the clinic. She holds a PhD and completed postdoctoral fellowships at Yale University and Johns Hopkins University. Her expertise spans target discovery, translational strategy, and building innovative research organizations.
Seminars
The future of RNAi lies at the intersection of precision medicine, AI-driven innovation, and strategic combination approaches. This panel explores how integrating cutting-edge technologies like AI target discovery with synergistic modalities can unlock new therapeutic potential. Experts will discuss multi-target silencing strategies, new target molecule classes, and how to future-proof RNAi pipelines to lead the next wave of transformative treatments. Join us to gain actionable insights on positioning your RNAi therapeutics at the forefront of precision medicine by discussing:
- Exploring AI-driven target discovery and combination therapies with CAR-T or radiotherapy to accelerate identification of disease-specific genes with high clinical relevance to enable faster precision RNAi therapy development
- Predicting future combination therapy strategies to stay ahead of emerging trends in multi-target silencing, for the expansion of treatment options for complex diseases
- Strategizing how to position pipelines at the forefront of next-gen RNAi innovation
- Understanding how the STRIKE™ platform utilizes proprietary ligand-siRNA conjugates (STRIKERs) for precise, receptor-mediated uptake in target kidney cells, minimizing systemic exposure and off-site toxicity.
- Exploring how megalin-STRIKERs are engineered to enhance cellular internalization into proximal tubule cells, improving the efficiency of gene silencing
- Evaluating how this targeted delivery approach enables potent and durable silencing, providing a long-term therapeutic strategy
